COGT (Cogent Biosciences) Total Liabilities: $295.31 Mil (As of Mar. 2026)


COGT Cogent Biosciences Inc COGT
25 GF Score
Price $38.05
! 5 Warning Signs
View Full Analysis

What is Cogent Biosciences Total Liabilities?

Cogent Biosciences COGT +0.26% 25 Total Liabilities is $295.31 Mil as of Mar. 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 5 warning signs investors should review.

Cogent Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was $295.31 Mil.

Cogent Biosciences's quarterly Total Liabilities increased from Sep. 2025 ($123.47 Mil) to Dec. 2025 ($301.24 Mil) but then declined from Dec. 2025 ($301.24 Mil) to Mar. 2026 ($295.31 Mil).

Cogent Biosciences's annual Total Liabilities increased from Dec. 2023 ($55.64 Mil) to Dec. 2024 ($71.61 Mil) and increased from Dec. 2024 ($71.61 Mil) to Dec. 2025 ($301.24 Mil).

Cogent Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences Total Liabilities Chart

Cogent Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.91 45.08 55.64 71.61 301.24

Cogent Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.80 119.78 123.47 301.24 295.31
COGT
25GF Score
Cogent Biosciences Inc COGT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogent Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cogent Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=63.953+(237.25+0.032999999999987
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=301.24

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=937.607-636.371
=301.24

Cogent Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=57.981+(237.27+0.061999999999983
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=295.31

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=903.006-607.693
=295.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $295.31 Mil mean?
Cogent Biosciences (COGT) has a Total Liabilities of $295.31 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cogent Biosciences and its competitors.
Is Cogent Biosciences' Total Liabilities too high?
Cogent Biosciences' current Total Liabilities is $295.31 Mil. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Total Liabilities compare to SRRK and RYTM?
Cogent Biosciences' Total Liabilities of $295.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cogent Biosciences and its competitors. Cogent Biosciences's current Total Liabilities is $295.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Total Liabilities of $295.31 Mil. The current Total Liabilities is $295.31 Mil. Cogent Biosciences' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Total Liabilities is $295.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score

Get the complete analysis for COGT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.05
Price